We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$121M
Cap. Flow %
-3.08%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Financials 0.15%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
26
DELISTED
Centessa Pharmaceuticals
CNTA
$19.1M 0.49%
2,112,500
+700,000
+50% +$6.64M
CGEM icon
27
Cullinan Oncology
CGEM
$1.26B
$18.5M 0.47%
+1,057,949
New +$22.5M
NAMS icon
28
NewAmsterdam Pharma
NAMS
$3.19B
$15.4M 0.39%
800,000
– –
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.21B
$14.9M 0.38%
381,554
+128,167
+51% +$5.12M
EWTX icon
30
Edgewise Therapeutics
EWTX
$4.69B
$14.6M 0.37%
811,718
– –
SLDB icon
31
Solid Biosciences
SLDB
$974M
$14.2M 0.36%
2,500,000
– –
KRRO icon
32
Korro Bio
KRRO
$196M
$14M 0.36%
413,072
-6,154
-1% -$340K
ASND icon
33
Ascendis Pharma A/S
ASND
$16.2B
$13.8M 0.35%
+101,100
New +$13.8M
AGEN
34
Agenus
AGEN
$315M
$13M 0.33%
775,000
-6,562
-0.8% -$79.3K
SYRS
35
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$12.9M 0.33%
2,505,013
– –
GOSS icon
36
Gossamer Bio
GOSS
$83.3M
$12M 0.31%
13,308,968
– –
DNLI icon
37
Denali Therapeutics
DNLI
$3.97B
$11.7M 0.3%
502,899
– –
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.6B
$11.3M 0.29%
275,000
+97,068
+55% +$4.14M
BHVN icon
39
Biohaven
BHVN
$2.24B
$10.6M 0.27%
+306,703
New +$12.1M
TSHA icon
40
Taysha Gene Therapies
TSHA
$1.92B
$9.75M 0.25%
4,354,214
+666,666
+18% +$1.94M
LXEO icon
41
Lexeo Therapeutics
LXEO
$407M
$9.68M 0.25%
603,435
-198,281
-25% -$2.88M
SLRN
42
DELISTED
ACELYRIN
SLRN
$8.91M 0.23%
2,020,888
-384,255
-16% -$1.8M
JANX icon
43
Janux Therapeutics
JANX
$978M
$8.5M 0.22%
203,000
+153,000
+306% +$7.18M
RNAC icon
44
Cartesian Therapeutics
RNAC
$264M
$8.23M 0.21%
304,554
-1
-0% -$24
RAPP
45
Rapport Therapeutics
RAPP
$2.27B
$8.14M 0.21%
+350,000
New +$8.1M
IOVA icon
46
Iovance Biotherapeutics
IOVA
$2.95B
$8.11M 0.21%
+1,011,500
New +$10.8M
GBIO
47
DELISTED
Generation Bio
GBIO
$7.98M 0.2%
283,059
– –
SEER icon
48
Seer Inc
SEER
$116M
$7.98M 0.2%
4,750,000
– –
VIGL
49
DELISTED
Vigil Neuroscience
VIGL
$7.31M 0.19%
1,828,691
+17,500
+1% +$59.9K
DFTX
50
Definium Therapeutics
DFTX
$5.9B
$7.27M 0.19%
+1,007,875
New +$8.81M
1
2
3 4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group withdrew a net $121M in Q2 2024, closing 20 positions and reducing 29 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $29.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Artal Group opened a new position in Cullinan Oncology worth $18.5M.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.